--- title: "Adaptimmune Therapeutics (ADAPY) news: delisting" url: "https://aibio.space/companies/adaptimmune-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ADAPY delisting news: Adaptimmune gets Nasdaq panel exception until December 1, 2025, to fix bid price." --- ADAPY Adaptimmune Therapeutics plc OTC · United Kingdom # Adaptimmune Therapeutics (ADAPY) news ADAPY delisting news Listings · 2025-09-26 ## [Adaptimmune gets Nasdaq panel exception until December 1, 2025, to fix bid price](https://aibio.space/news/adaptimmune-gets-nasdaq-panel-exception-until-december-1-2025-fix-bid/) A Nasdaq Hearings Panel gave Adaptimmune until December 1, 2025 to meet the $1.00 minimum bid price, or its American Depositary Shares will be delisted. The 8-K gives no share price and no count of days below the floor. ## Latest Adaptimmune Therapeutics news 1. 2025-07-31 Mergers [Adaptimmune sells cell therapy assets to US WorldMeds for $55 million upfront](https://aibio.space/news/adaptimmune-sells-cell-therapy-assets-us-worldmeds-55-million-upfront/) Adaptimmune sold its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to a US WorldMeds subsidiary for $55 million in cash at closing, with up to $30 million more on milestones. The $134 million gain is a pro forma estimate built on March 31, 2025 values. ## Adaptimmune Therapeutics at a glance - **Ticker**: ADAPY - **Listing**: OTC - **Country**: United Kingdom - **Cash, Jun 30, 2025**: $26.1 million ### Related companies - [COMPASS Pathways Plc](https://aibio.space/companies/compass-pathways/) NASDAQ: CMPS - [OptiBiotix Health](https://aibio.space/companies/optibiotix-health/) LSE: OPTI - [Nuformix Plc](https://aibio.space/companies/nuformix/) LSE: NFX - [NuCana](https://aibio.space/companies/nucana/) NASDAQ: NCNA - [Mereo BioPharma Group](https://aibio.space/companies/mereo-biopharma/) NASDAQ: MREO - [Oxford BioMedica](https://aibio.space/companies/oxford-biomedica/) LSE: OXB - [HemoGenyx Pharmaceuticals Plc](https://aibio.space/companies/hemogenyx-pharmaceuticals/) LSE: HEMO - [Diaceutics Plc](https://aibio.space/companies/diaceutics/) LSE: DXRX ### Also on OTC - [INTERPACE BIOSCIENCES, INC.](https://aibio.space/companies/interpace-biosciences/) IDXG - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) LIFS - [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) MCET - [ZENITH CAPITAL CORPORATION](https://aibio.space/companies/zenith-capital/) ZHCLF - [Virpax Pharmaceuticals](https://aibio.space/companies/virpax-pharmaceuticals/) VRPX - [Cannabis Bioscience International Holdings](https://aibio.space/companies/cannabis-bioscience-international/) CBIH ## What Adaptimmune Therapeutics does Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company developing engineered T-cell therapies for solid tumor cancers. Its first product, TECELRA (afamitresgene autoleucel), is approved in the U.S. for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumor expresses the MAGE-A4 antigen. The approval is an accelerated approval based on overall response rate and duration of response. The company is planning commercial launch of its second T-cell therapy, letetresgene autoleucel (lete-cel), which targets the NY-ESO antigen and has been studied in synovial sarcoma and myxoid liposarcoma. The FDA granted lete-cel breakthrough therapy designation in January 2025 for myxoid liposarcoma. A collaboration with Galapagos uses uzatresgene autoleucel (uza-cel), made on Galapagos' decentralized manufacturing platform, in a clinical proof-of-concept trial in head and neck cancer. Preclinical programs target PRAME and CD70. In late 2024 the company ceased investment in non-core programs and reduced headcount by approximately 29%, and it is evaluating all strategic options for the company and its programs. | Product or program | What it is | Stage | |---|---|---| | TECELRA (afamitresgene autoleucel) | Engineered T-cell therapy for MAGE-A4-positive synovial sarcoma | approved in the US | | lete-cel (letetresgene autoleucel) | NY-ESO-targeted T-cell therapy for synovial sarcoma and myxoid liposarcoma | breakthrough therapy designation for myxoid liposarcoma | | uza-cel (uzatresgene autoleucel) | Engineered T-cell receptor therapy for head and neck cancer, with Galapagos | Phase 1 trial planned | | ADP-600 | Preclinical T-cell therapy directed to PRAME | preclinical | | ADP-520 | Preclinical T-cell therapy directed to CD70 | preclinical | Summarised from the company's [10-K filed Mar 24, 2025](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/adap-20241231x10k.htm). ## Adaptimmune Therapeutics annual financials | Line | FY2024 | FY2023 | |---|---|---| | Revenue | [$178.0 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | [$60.3 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | | Research and development | [$149.1 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | [$126.5 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | | Net income (loss) | [-$70.8 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | [-$113.9 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | | Cash from operations | [-$73.2 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | [-$140.9 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | | Cash and equivalents | [$91.1 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/) | [$144.0 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | | Short-term investments | [$60.5 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/) | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003544/) | Latest balance sheet, Jun 30, 2025 (10-Q): cash and equivalents $26.1 million, plus short-term investments of $0, $26.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Adaptimmune Therapeutics Was Adaptimmune Therapeutics delisted? Our latest story on this, dated Sep 26, 2025: "Adaptimmune gets Nasdaq panel exception until December 1, 2025, to fix bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/adaptimmune-gets-nasdaq-panel-exception-until-december-1-2025-fix-bid/). What is the ticker symbol of Adaptimmune Therapeutics? Adaptimmune Therapeutics plc trades under the ticker ADAPY on OTC. Where is Adaptimmune Therapeutics listed? Adaptimmune Therapeutics plc is listed on OTC. What is the SEC CIK of Adaptimmune Therapeutics? The SEC Central Index Key (CIK) for Adaptimmune Therapeutics plc is 1621227. Its filings are on SEC EDGAR. How many shares does Adaptimmune Therapeutics have outstanding? 1,590,309,546 shares as of 2025-08-11, per the cover page of its 10-Q filed 2025-08-13. Which country or territory is Adaptimmune Therapeutics listed under? Our directory records Adaptimmune Therapeutics plc under United Kingdom. What does Adaptimmune Therapeutics do? Our directory classifies Adaptimmune Therapeutics plc as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Adaptimmune Therapeutics? The ISIN recorded for Adaptimmune Therapeutics plc is US00653A1079. Does aibio.space cover Adaptimmune Therapeutics? aibio.space lists Adaptimmune Therapeutics plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Adaptimmune Therapeutics incorporated? SEC records list its state or country of incorporation as X0. What does Adaptimmune Therapeutics develop? Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company developing engineered T-cell therapies for solid tumor cancers. Its first product, TECELRA (afamitresgene autoleucel), is approved in the U.S. for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumor expresses the MAGE-A4 antigen. What is TECELRA (afamitresgene autoleucel) from Adaptimmune Therapeutics? TECELRA (afamitresgene autoleucel): Engineered T-cell therapy for MAGE-A4-positive synovial sarcoma Stage: approved in the US. What is lete-cel (letetresgene autoleucel) from Adaptimmune Therapeutics? lete-cel (letetresgene autoleucel): NY-ESO-targeted T-cell therapy for synovial sarcoma and myxoid liposarcoma Stage: breakthrough therapy designation for myxoid liposarcoma. What was Adaptimmune Therapeutics's revenue last year? $178.0 million for the fiscal year ended Dec 31, 2024, as reported to the SEC. Is Adaptimmune Therapeutics profitable? Adaptimmune Therapeutics plc reported a net loss of $70.8 million for the fiscal year ended Dec 31, 2024, and used $73.2 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Adaptimmune Therapeutics Members talk about Adaptimmune Therapeutics (ADAPY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Adaptimmune Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-11-13 Listings Filed to end its SEC reporting. SEC Form 15-12G. [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925110847/tm2530966d1_1512g.htm) 2. 2025-10-28 Listings Filed to remove its shares from exchange listing. SEC Form 25. [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925102828/tm2528948d4_25.htm) 3. 2025-10-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925100618/adap-20251015xex99d1.htm) 4. 2025-09-26 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/adap-20250922x8k.htm) 5. 2025-09-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/adap-20250911x8k.htm) 6. 2025-08-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011579/adap-20250814x8k.htm) 7. 2025-07-31 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.02,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/tm2522092d1_ex99-1.htm) 8. 2025-07-28 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925071009/tm2521829d1_ex99-1.htm) 9. 2025-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925043522/tm2513768d1_8k.htm) 10. 2025-04-18 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1621227/000110465925036359/tm2512500-1_s3.htm) 11. 2025-03-20 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000155837025003340/adap-20250320xex99d1.htm) 12. 2024-12-19 Distress Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000155837024016371/adap-20241218xex99d1.htm) 13. 2024-11-13 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000155837024015525/adap-20241113xex99d1.htm) 14. 2024-11-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1621227/000155837024015532/adap-20240930x10q.htm) 15. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1621227/000155837024014148/adap-20241101x8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:ADAPY on TradingView](https://www.tradingview.com/symbols/OTC-ADAPY/). ## SEC filings and registration - **SEC name**: Adaptimmune Therapeutics PLC - **CIK**: 1621227 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ADAPY (OTC) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE - **Phone**: 44 1235 430000 - **Shares outstanding**: 1,590,309,546 as of 2025-08-11 (10-Q filed 2025-08-13) - **Former names**: Adaptimmune Ltd ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000110465925100618/adap-20251015x8k.htm) filed 2025-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000110465925093882/adap-20250922x8k.htm) filed 2025-09-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000110465925089558/adap-20250911x8k.htm) filed 2025-09-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011925/adap-20250906x8k.htm) filed 2025-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011820/adap-20250829x8k.htm) filed 2025-08-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011616/adap-20250815x8k.htm) filed 2025-08-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011579/adap-20250814x8k.htm) filed 2025-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/adap-20250630x10q.htm) filed 2025-08-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001621227), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Adaptimmune Therapeutics plc is a public biotech or pharmaceutical company listed on OTC under the ticker ADAPY, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Adaptimmune Therapeutics plc - **Ticker**: ADAPY - **Listing**: OTC - **Country or territory**: United Kingdom - **Business scope**: Biotechnology - **ISIN**: US00653A1079 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-ADAPY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/adaptimmune-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Adaptimmune Therapeutics (ADAPY) news: delisting", 2026-10-31, https://aibio.space/companies/adaptimmune-therapeutics/